Client results
Imugene Limited A$46 million Capital Raise
McCullough Robertson’s Equity Capital Markets and Life Sciences team has assisted clinical stage immuno-oncology company, Imugene Limited (Imugene) in securing a capital injection of up to A$46 million to support its clinical trial pipeline via the issue of convertible notes and warrants to CVI Investments Inc.
The issuance, which involves A$20 million of convertible notes and up to a further A$26 million through the issue of unlisted warrants, provides Imugene with pivotal up-front funding, while avoiding the traditional drawbacks of other convertible notes.
The capital raised will be used for Imugene’s ongoing clinical trials for its azer-cel, onCARlytics, and VAXINIA programs for the treatment of solid tumours and blood cancers.
The McCullough Robertson team, led by Partner Reece Walker, has proudly supported Imugene since 2013.